Profusa, a digital health company, announced its Board of Directors has launched a process to explore strategic alternatives such as partnerships, business combinations, or asset sales to maximize shareholder value. The company is focusing on near-term goals including advancing CE Mark approval for its Lumee Oxygen platform in Europe and growing revenue from its Healthcare Research business. Profusa has engaged Tungsten Advisors to assist in identifying and executing potential strategic opportunities. The process aims to strengthen the company's scale, execution, and long-term growth prospects, but no specific transaction is guaranteed yet.
Aditxt Inc. shares dropped 33.94% in after-hours trading following a disclosure that major shareholder HRT Financial LP purchased over 4.2 million shares at $0.016 each. Despite this large purchase, the stock continues to face heavy selling pressure,...
Investors who sold Activision Blizzard stock between January 18, 2022, and October 13, 2023, have until June 30, 2026, to apply to be lead plaintiffs in a class action lawsuit. The suit alleges that Activision Blizzard and its board made false and mi...
Integrated Research has introduced Iris for Nonstop, a conversational AI integrated into the Prognosis Platform for HPE Nonstop systems. This AI tool enables IT teams and business stakeholders to ask natural language questions about system health, pe...
Defiance ETFs has introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed to provide twice the inverse daily performance of SpaceX stock (SPCX). This ETF targets active traders seeking short-term bearish exposure to SpaceX, a leadin...
Defiance ETFs introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed to provide investors with double inverse exposure to SpaceX's daily stock price movements. This ETF aims to deliver -200% of SpaceX's daily returns, allowing inve...
